Bristol-Myers Squibb and Nektar collaborate to test Opdivo and NKTR-214 combination

Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) have entered a new clinical collaboration to test the combination of Opdivo (nivolumab) and NKTR-214 to treat five tumour types and seven other indications.

Source: Drug Development Technology - September 28, 2016 Category: Pharmaceuticals Source Type: news